CANSINOBIO(06185),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06185 CANSINOBIO

Closed 07-02 16:08:21

23.200

+0.920

+4.13%

High24.080	Low22.640	Vol1.14M
Open22.640	D1 Closing22.280	Amplitude6.46%
Mkt Cap5.73B	Tradable Cap3.08B	Total Shares247.04M
T/O26.69M	T/O Rate0.86%	Tradable Shares132.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"CANSINOBIO","latestPrice":23.2,"timestamp":1782979701006,"preClose":22.28,"halted":0,"volume":1138592,"delay":0,"changeRate":0.04129263913824049,"floatShares":132670900,"shares":247043801,"eps":0.11,"marketStatus":"Closed","change":0.92,"latestTime":"07-02 16:08:21","open":22.64,"high":24.08,"low":22.64,"amount":26686805,"amplitude":0.064632,"askPrice":23.26,"askSize":200,"bidPrice":23.2,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-0.005,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1783042200000},"marketStatusCode":5,"adr":0,"listingDate":1553702400000,"exchange":"SEHK","adjPreClose":22.28,"openAndCloseTimeList":[[1782955800000,1782964800000],[1782968400000,1782979200000]],"volumeRatio":1.31988,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"Cansino Biologics Inc.","latestPrice":52.38,"timestamp":1782975600000,"preClose":53.07,"halted":0,"volume":2315200,"delay":0,"premium":"-61.66"}},"requestUrl":"/m/hq/s/06185/wiki","defaultTab":"wiki","newsList":[{"id":"2646779468","title":"CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Argentina","url":"https://stock-news.laohu8.com/highlight/detail?id=2646779468","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646779468?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:42","pubTimestamp":1782387769,"startTime":"0","endTime":"0","summary":"CanSino Biologics'  ACYW135 Meningococcal Polysaccharide Conjugate Vaccine received a drug registration certificate from the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica.The product is used for the prevention of epidemic cerebrospinal meningitis associated with ACYW135 Neisseria meningitidis, according to a Thursday Hong Kong bourse filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK1191","06185","BK1161","BK1515","BK1574","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176634791","title":"CanSino Biologics: MCV4 Vaccine Gains Argentine Registration, Advancing Global Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1176634791","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176634791?lang=en_us&edition=fundamental","pubTime":"2026-06-25 17:23","pubTimestamp":1782379439,"startTime":"0","endTime":"0","summary":"CanSino Biologics Inc. announced that its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), marketed as Menhycia®, has received a drug registration certificate from Argentina’s...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105569847","title":"CansinoBIO Secures Regulatory Approval in Argentina for Meningococcal Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1105569847","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105569847?lang=en_us&edition=fundamental","pubTime":"2026-06-25 17:16","pubTimestamp":1782378995,"startTime":"0","endTime":"0","summary":"The pharmaceutical company CansinoBIO (06185) has announced that its ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector), known as MCV4 and marketed under the brand name...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","BK1515","BK1161","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192316806","title":"CanSino Biologics Defines Governance, Capital Structure and Dividend Policy in Updated Articles of Association","url":"https://stock-news.laohu8.com/highlight/detail?id=1192316806","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192316806?lang=en_us&edition=fundamental","pubTime":"2026-06-10 20:45","pubTimestamp":1781095542,"startTime":"0","endTime":"0","summary":"Tianjin-headquartered vaccine developer CanSino Biologics (CANSINOBIO) has released its revised Articles of Association, setting out detailed rules on share capital, corporate governance, profit...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136964109","title":"CANSINOBIO Keeps Share Capital Steady in May; 2.91 Million Shares Reserved for Incentive Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=1136964109","media":"Bulletin Express","labels":["SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136964109?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:46","pubTimestamp":1780389987,"startTime":"0","endTime":"0","summary":"CanSino Biologics Inc. (CANSINOBIO) reported no changes in either authorised or issued share capital for the month ended 31 May 2026, maintaining balance-sheet stability across both its Hong...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638456120","title":"CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2638456120","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638456120?lang=en_us&edition=fundamental","pubTime":"2026-05-26 10:09","pubTimestamp":1779761340,"startTime":"0","endTime":"0","summary":"CanSino Biologics  initiated a phase 1/2 trial of its 24-valent pneumococcal conjugate vaccine, a broad-spectrum shot designed to prevent infections caused by 24 pneumococcal serotypes, according to a Tuesday filing with the Hong Kong bourse.The trial will evaluate the vaccine in subjects aged two months and older for the prevention of pneumococcal infections, which can cause diseases such as pneumonia and meningitis.The new product could expand coverage beyond the company's existing 13-valent pneumococcal vaccine, which was approved in China in June 2025.The firm said there were currently no 24-valent pneumococcal conjugate vaccines available on the global market.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1161","BK1574","BK0239","06185","688185","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194186054","title":"CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled","url":"https://stock-news.laohu8.com/highlight/detail?id=1194186054","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194186054?lang=en_us&edition=fundamental","pubTime":"2026-05-26 08:26","pubTimestamp":1779755182,"startTime":"0","endTime":"0","summary":"CANSINOBIO (06185) announced that the Phase I/II clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), PCV24, has officially commenced, with the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1191","BK1515","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149227006","title":"CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=1149227006","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149227006?lang=en_us&edition=fundamental","pubTime":"2026-05-26 08:25","pubTimestamp":1779755154,"startTime":"0","endTime":"0","summary":"CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111891658","title":"CANSINOBIO Sets 2025 AGM for 10 June 2026; Seeks Share-Issuance, Repurchase and Dividend Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1111891658","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111891658?lang=en_us&edition=fundamental","pubTime":"2026-05-19 17:04","pubTimestamp":1779181461,"startTime":"0","endTime":"0","summary":"CanSino Biologics Inc. (CANSINOBIO) will convene its 2025 Annual General Meeting on 10 June 2026 at 1:30 p.m. in Tianjin. Shareholders of record are entitled to vote in person or by proxy, with proxy...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138410690","title":"CANSINOBIO Calls 10 June 2026 AGM to Approve 2025 Results, No Dividend Payout, and Fresh Financing Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1138410690","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138410690?lang=en_us&edition=fundamental","pubTime":"2026-05-19 16:43","pubTimestamp":1779180221,"startTime":"0","endTime":"0","summary":"CanSino Biologics Inc. (CANSINOBIO) has scheduled its 2025 Annual General Meeting (AGM) for 10 June 2026 in Tianjin. Shareholders will vote on 15 resolutions that cover performance review, profit...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634024714","title":"CanSino Biologics' Drug Application for Combined Vaccines Granted Priority Review in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2634024714","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634024714?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:55","pubTimestamp":1778493301,"startTime":"0","endTime":"0","summary":"CanSino Biologics'  new drug application for its Tetanus, Reduced Diphtheria, and Pertussis Combined Vaccine, Adsorbed, was granted priority review status by China's National Medical Products Administration.The vaccine is a booster vaccine for diphtheria, tetanus, and acellular pertussis for adolescents and adults aged six years and above, according to a Monday Hong Kong bourse filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK1191","BK1515","BK1574","06185","BK1161","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197499820","title":"CansinoBIO's Td5cp Vaccine for Adolescents and Adults Granted Priority Review by China's Drug Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1197499820","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197499820?lang=en_us&edition=fundamental","pubTime":"2026-05-11 16:52","pubTimestamp":1778489542,"startTime":"0","endTime":"0","summary":"CansinoBIO (06185) announced that the New Drug Application (NDA) for its Adsorbed Acellular Pertussis (Five-Component), Diphtheria, and Tetanus Combined Vaccine for individuals aged 6 and above...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","BK1191","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631658493","title":"CanSino Biologics Q1 Loss After Two Profitable Quarters Tests Bullish Profitability Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2631658493","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631658493?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:22","pubTimestamp":1777544556,"startTime":"0","endTime":"0","summary":"CanSino Biologics (SEHK:6185) opened Q1 2026 with total revenue of C¥190.3 million and a basic EPS loss of C¥0.16 per share, setting a cautious tone for the latest update. Over the past year, revenue on a trailing twelve month basis has moved from C¥846.3 million in Q4 2024 to C¥1.1 billion in Q1 2026, while trailing EPS has shifted from a loss of C¥1.53 to a much smaller loss of C¥0.00 per share. This puts the focus squarely on how far the company has come in narrowing losses and what that...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-q1-loss-after-two-profitable-quarters-test","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-q1-loss-after-two-profitable-quarters-test","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","688185","BLSX","BK4112","BLSG","BK1191","06185","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171896997","title":"UBS Lowers CANSINOBIO (06185) Target Price to HK$52.4, Q1 Results In Line","url":"https://stock-news.laohu8.com/highlight/detail?id=1171896997","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171896997?lang=en_us&edition=fundamental","pubTime":"2026-04-30 16:16","pubTimestamp":1777537001,"startTime":"0","endTime":"0","summary":"UBS has released a research report stating that CANSINOBIO's (06185) first-quarter performance for the year met expectations. During the period, revenue reached 190 million yuan, representing a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1191","BK1515","BK1574","EWH","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176339495","title":"CanSinoBIO Proposes Comprehensive Amendments to Articles and Board Procedures to Strengthen Governance","url":"https://stock-news.laohu8.com/highlight/detail?id=1176339495","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176339495?lang=en_us&edition=fundamental","pubTime":"2026-04-28 17:04","pubTimestamp":1777367059,"startTime":"0","endTime":"0","summary":"CanSino Biologics Inc. (“CanSinoBIO”) convened the eleventh meeting of its third-session Board of Directors on 28 April 2026 and approved a package of proposed amendments to the company’s Articles of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153788302","title":"CANSINOBIO Reports Widened Net Loss in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=1153788302","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153788302?lang=en_us&edition=fundamental","pubTime":"2026-04-28 17:02","pubTimestamp":1777366947,"startTime":"0","endTime":"0","summary":"CANSINOBIO (06185) announced its financial results for the three months ended March 31, 2026. The company reported an operating revenue of 190 million yuan, representing a year-on-year increase of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","06185","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162509839","title":"康希诺生物2025年业绩扭亏为盈，核心疫苗销售推动营收突破10.59亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162509839","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162509839?lang=en_us&edition=fundamental","pubTime":"2026-04-22 17:08","pubTimestamp":1776848923,"startTime":"0","endTime":"0","summary":"康希诺生物（股票代码：06185）于2025年再现显著业绩转折，全年实现净利润0.28亿元（人民币，下同），相较2024年亏损3.84亿元大幅改善。同时，2025年营业收入达10.59亿元，较2024年的8.25亿元增长28.4%，并接近2022年创下的10.31亿元高位。在销售规模扩大与成本管控优化的带动下，公司于2025年录得经营利润0.44亿元，扭转了连续三年的经营亏损局面。...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物2025年业绩扭亏为盈，核心疫苗销售推动营收突破10.59亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157234626","title":"CANSINOBIO 2025 ESG Report: GHG Intensity Cut 17.39%, RMB 371 Million R&D Outlay and Multiple Vaccine Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=1157234626","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157234626?lang=en_us&edition=fundamental","pubTime":"2026-04-22 17:07","pubTimestamp":1776848845,"startTime":"0","endTime":"0","summary":"CANSINOBIO has released its 2025 Environmental, Social and Governance (ESG) & Sustainability Report, detailing progress on climate action, product innovation and corporate governance. Environmental...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161032998","title":"CanSinoBIO reiterates switch to electronic corporate communications, requests shareholders’ email registration","url":"https://stock-news.laohu8.com/highlight/detail?id=1161032998","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161032998?lang=en_us&edition=fundamental","pubTime":"2026-04-22 17:06","pubTimestamp":1776848819,"startTime":"0","endTime":"0","summary":"CanSino Biologics Inc. (CanSinoBIO) reminded registered shareholders on 22 April 2026 that the company has fully adopted electronic dissemination of all future corporate communications. English and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154636050","title":"CANSINOBIO Schedules 28 April Board Meeting to Approve Q1 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1154636050","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154636050?lang=en_us&edition=fundamental","pubTime":"2026-04-16 16:43","pubTimestamp":1776328982,"startTime":"0","endTime":"0","summary":"CanSino Biologics Inc. (CANSINOBIO) has notified the market that its board of directors will convene on 28 April 2026 to review and approve the consolidated financial results for the three‐month...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":0.022},{"period":"1month","weight":-0.1371},{"period":"3month","weight":-0.3412},{"period":"6month","weight":-0.362},{"period":"1year","weight":-0.3533},{"period":"ytd","weight":-0.362}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.030578},{"month":2,"riseRate":0.857143,"avgChangeRate":0.172684},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.060436},{"month":4,"riseRate":0.625,"avgChangeRate":0.049828},{"month":5,"riseRate":0.25,"avgChangeRate":-0.051769},{"month":6,"riseRate":0.5,"avgChangeRate":0.015607},{"month":7,"riseRate":0.571429,"avgChangeRate":0.056212},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.143307},{"month":9,"riseRate":0.714286,"avgChangeRate":0.068326},{"month":10,"riseRate":0.428571,"avgChangeRate":0.059174},{"month":11,"riseRate":0.571429,"avgChangeRate":0.088604},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.035813}],"exchange":"SEHK","name":"CANSINOBIO","nameEN":"CANSINOBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CANSINOBIO(06185),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CANSINOBIO(06185) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CANSINOBIO,06185,CANSINOBIO股票,CANSINOBIO股票老虎,CANSINOBIO股票老虎国际,CANSINOBIO行情,CANSINOBIO股票行情,CANSINOBIO股价,CANSINOBIO股市,CANSINOBIO股票价格,CANSINOBIO股票交易,CANSINOBIO股票购买,CANSINOBIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CANSINOBIO(06185),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CANSINOBIO(06185) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}